ClinConnect ClinConnect Logo
Search / Trial NCT06736860

Tranexamic Acid in Patients With Traumatic Bleeding Based on Dynamic Monitoring of Thromboelastography

Launched by NANFANG HOSPITAL, SOUTHERN MEDICAL UNIVERSITY · Dec 15, 2024

Trial Information

Current as of September 08, 2025

Recruiting

Keywords

Trauma Coagulopathy Tranexamic Acid Thromboelastography

ClinConnect Summary

This clinical trial is studying the use of a medication called tranexamic acid (TXA) in patients who have experienced traumatic bleeding. The goal is to see if giving TXA in a tailored way, based on real-time monitoring of blood clotting, can help reduce the risk of death after a traumatic injury. The researchers want to compare the standard method of giving TXA (a one-time dose followed by a steady infusion) with a new approach that allows for additional doses if needed. This could potentially improve survival rates and make the treatment safer.

To be eligible for the trial, participants must be between 18 and 80 years old and have certain criteria, such as low blood pressure or a rapid heart rate due to trauma. They also need to start receiving TXA within three hours of their injury. Participants will be closely monitored during the study, and the researchers will be looking at how effective the treatment is in preventing complications from bleeding. This trial is important because it aims to improve how TXA is used in trauma cases, which could lead to better outcomes for patients.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. . trauma patients 18 -80 years of age (50 points \> trauma ISS score \> 16);
  • 2. . hypotension (systolic blood pressure ≤ 90 mm Hg) and/or tachycardia (heart rate ≥ 110 beats/min);
  • 3. . receiving a 1 g TXA push within 3 h of the injury, with the push completed within 10 min of arrival at the hospital.
  • 4. . signing the informed consent form.
  • Exclusion Criteria:
  • 1. .Coagulation abnormalities due to co-morbid hematologic or autoimmune diseases
  • 2. Inability to establish venous or intraosseous access
  • 3. Pregnant women
  • 4. Traumatic cardiac arrest for more than 5 minutes
  • 5. Failure of cardiopulmonary resuscitation
  • 6. Penetrating brain injury
  • 7. Drowning or hanging -

About Nanfang Hospital, Southern Medical University

Nanfang Hospital, affiliated with Southern Medical University, is a leading medical institution in China renowned for its comprehensive clinical services and commitment to advancing healthcare through research and education. As a clinical trial sponsor, Nanfang Hospital leverages its state-of-the-art facilities and a multidisciplinary team of expert researchers to conduct innovative studies aimed at improving patient outcomes and contributing to the global medical community. The hospital's focus on ethical standards and patient safety ensures that all trials are conducted with the highest level of integrity and scientific rigor.

Locations

Guangzhou, Guangdong, China

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported